{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-039334","form_type":"8-K","ticker":"HCWB","cik":"0001828673","company_name":"HCW Biologics Inc.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.470379+00:00","generated_at":"2026-06-04T04:51:12.597834+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"HCW Biologics FY 2023 net loss $25M vs $14.9M; going concern substantial doubt; $12.5M new financing","bullets":["FY 2023 revenue $2.8M (down 58% from $6.7M); net loss $25.0M vs $14.9M in 2022.","Reserve for credit loss of $5.3M on terminated Prime Capital Ventures credit agreement.","Completed $2.5M private placement (Feb 2024) and $10.0M secured notes (Mar 2024); substantial doubt about going concern as of Dec 31, 2023.","Phase 1/1b trials of HCW9218 completed; planning Phase 2 in ovarian and pancreatic cancer.","Arbitration with Altor/NantCell scheduled for May 2024; new Delaware complaint for contribution of legal fees."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-039334","json":"https://secwatch.observer/filing/0000950170-24-039334.json","markdown":"https://secwatch.observer/filing/0000950170-24-039334.md","text":"https://secwatch.observer/filing/0000950170-24-039334.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828673/000095017024039334/0000950170-24-039334-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828673/000095017024039334/hcwb-20240401.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:51:12.597834+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d0f27999beebe9728de1cdcc422f70fa45330299","claim":"HCW Biologics Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2023.","evidence_excerpt":"On April 1, 2024, HCW Biologics Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828673/000095017024039334/0000950170-24-039334-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}